CD34 and acute myeloid leukemia: Consistent with the results observed in the LSC-like cell lines, cotreatment of primary CD34+ AML cells with chidamide and apatinib resulted in significant increases in the percentage of the apoptotic cells when compared with each single agent (Fig. 3A, B).